Please amend the application as follows:

In the specification:

Delete the paragraph running from line 1 through line 8 of page 3 and replace it with:

The salts of the invention may be used as selective 5-$HT_{1A}$ receptor antagonists in the treatment of CNS disorders and related medical disturbances. Examples of such disorders are depression, anxiety, obsessive-compulsive disorder (OCD), anorexia, bulimia, senile dementia, migraine, stroke, Alzheimer's disease, cognitive disorders, schizophrenia, especially cognitive dysfunction in schizophrenia, sleep disorders, urinary incontinence, premenstrual syndrome, hypertension and pain. Examples of such medical disturbances are thermoregulatory disturbances, sexual disturbances, disturbances in the cardiovascular system and disturbances in the gastrointestinal system.

In the claims:

Cancel claims 1, 2, 11 and 19. Replace pending claims 4, 5, 12-18 and 20 with the amended versions below. Add new claims 21 and 22 as set forth below.

4. (twice amended) The salt according to claim 3 in crystalline form.

5. (twice amended) A pharmaceutical formulation containing, as active ingredient, the salt according to claim 3 or 4 in association with a suitable diluent, excipient or an inert carrier.

12. (thrice amended) A method for the treatment of 5-hydroxytryptamine$_{1A}$-receptor-antagonist-activity-related central nervous system disorders or so related thermoregulatory disturbances, sexual disturbances, disturbances in the cardiovascular system or disturbances in the gastrointestinal system comprising administering, to a host in need of such treatment, an effective amount of the salt according to claim 3 or 4.

13. (thrice amended) A method according to claim 12 for the treatment of obsessive-compulsive disorder, anorexia, bulimia, senile dementia, migraine, stroke, Alzheimer's disease, cognitive disorders, pre-menstrual syndrome, hypertension or pain.

14. (amended) A method according to claim 12 for the treatment of depression.

15. (amended) A method according to claim 12 for the treatment of anxiety.

16. (twice amended) A process of making the salt as defined in claim 3 or 4 which comprises the following consecutive steps:

i) dissolving (*R*)-3-*N*,*N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-1-benzopyran-5-carboxamide in an appropriate solvent, optionally by heating,

ii) adding (2*R*,3*R*)-tartaric acid dissolved in an appropriate aqueous organic solvent or non-aqueous organic solvent,

iii) allowing the solution obtained to stand cold to crystallize,

iv) optionally recrystallizing in an appropriate aqueous organic solvent, if a non-aqueous organic solvent is used in step ii), to obtain the salt defined in claim 3 or 4.

17. (thrice amended) A process of making the salt as defined in claim 3 or 4 which comprises a final step of recrystallizing (*R*)-3-*N*,*N*-dicyclobutylamino-8-fluoro-3,4-dihydro-2*H*-benzopyran-5-carboxamide hydrogen (2*R*,3*R*)-tartrate in an appropriate aqueous organic solvent.

18. (twice amended) A process according to claim 16, wherein the aqueous organic solvent is aqueous acetone.

20. (amended) A method according to claim 12 for the treatment of urinary incontinence.

21. (new) A pharmaceutical formulation according to claim 5 for oral administration.

22. (new) A process according to claim 17, wherein the aqueous organic solvent is aqueous acetone.